PubMed HealthSearch

Biomedical subjects

M Stoopler

Publications and source records attributed to M Stoopler.

6 recordsLinked to original sources

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.

The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin-based combinations, cisplatin-cytarabine (ara-C) and cisplatin-vinblastine, in 151 patients with advanced non-small cell lung cancer. Patients entered on study had not received prior chemotherapy. Platinum doses were equivalent in the two treatment programs. The total response rate (complete response, partial response, regression of evaluable disease) for the cisplatin-vinblastine group was 22% (16/73). Failure-free survival at six months for this group was 41%, survival at six months was 63%. The cisplatin-ara-C group had a total response rate of 9% (7/78) with a failure-free survival at six months of 14% and a six-month survival of 47%. Severe or life-threatening toxicity was seen in 73% of cisplatin-vinblastine cases and 59% of cisplatin-ara-C patients. Neither regimen is active enough to warrant designation as "standard therapy" for patients with M1 disease.

Aged

Aggressive insulinoma with bone metastases.

This is the first report of the development of bone metastases in a patient with an insulinoma. Following the development of bone metastases, further chemotherapy with etoposide (VP-16) and cis-platinum was not successful and the patient's condition was rapidly fatal. This case demonstrates the unusually aggressive course and poor response to currently available chemotherapeutic agents of a malignant insulinoma. The clinical and diagnostic features of insulinomas are reviewed.

Adenoma, Islet Cell

Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis.

A randomized, double blind crossover trial compared the antiemetic effects of alizapride, a benzamide, and prochlorperazine, a phenothiazine, both administered intravenously to 32 patients treated with chemotherapy combinations containing cisplatin. The total dose of alizapride administered to each patient was 14 mg/kg, and of prochlorperazine .56 mg/kg, divided in five doses. Although alizapride resulted in complete protection against emesis in 31% of the patients during their first course of cisplatin therapy, 42% of those who received alizapride had five or more episodes of emesis. Although prochlorperazine was less effective in offering complete protection against emesis, only 15% of the patients receiving this drug vomited more than five times. The duration of emesis during prochlorperazine treatment was also significantly shorter than during alizapride therapy (p less than 0.02). Optimal dosage and pharmacokinetic distribution of both drugs should be investigated further.

Adult

Systemic sclerosis and regional enteritis occurring simultaneously.

A 58-year-old white female who had regional enteritis for many years insidiously developed scleroderma. A review of the literature failed to reveal any previous reports of this combination of diseases. The possible etiologies of both diseases are discussed along with their overlapping clinical manifestations.

Colostomy

Waterborne gastrointestinal illness at a ski resort. --Isolation of Yersinia enterocolitica from drinking water--.

Approximately 41 percent of the visitors and employees who were at a ski resort in Montana between December 23, 1974, and January 17, 1975, became ill with diarrhea and other gastrointestinal symptoms. The association between illness and water consumption proved to be significant, and the previously noncontaminated water supply was found to contain coliforms. No pathogens except Yersinia enterocolitica were isolated, and it was isolated from two wells serving the area. The role of Y. enterocolitica in this outbreak is not clear, but it was the only organism isolated that is known to be pathogenic.

Adult